Mounjaro vs Zepbound: Tirzepatide for Diabetes vs Weight Loss

Mounjaro and Zepbound contain the identical active molecule — tirzepatide — manufactured by Eli Lilly. If you held a Mounjaro pen and a Zepbound pen of the same strength side by side, the medication inside would be the same. The reason they exist as two products is regulatory: the U.S. Food and Drug Administration approves drugs for specific indications (conditions), and Lilly pursued separate approvals for diabetes and for weight management.

Tirzepatide was first approved as Mounjaro in 2022 for type 2 diabetes, as an adjunct to diet and exercise to improve glycemic control. In 2023, the FDA approved the same molecule as Zepbound for chronic weight management in adults who meet the label's weight criteria. In late 2024, Lilly announced FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity as well.

This matters because you generally cannot ask a provider to write you Mounjaro 'for weight loss' or Zepbound 'for diabetes.' The brand a licensed clinician prescribes follows your diagnosis — which is what makes the prescription legitimate and, often, what makes insurance billing possible.

Tirzepatide is described in its FDA labeling as a dual GIP and GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are gut hormones involved in blood sugar regulation and appetite signaling. By acting on both receptors, tirzepatide influences insulin response and appetite. This dual mechanism is what distinguishes tirzepatide from older GLP-1-only drugs such as semaglutide (the molecule in Ozempic and Wegovy).

The clinical-trial findings for tirzepatide are reported in Lilly's prescribing information and in published studies such as the SURPASS program (diabetes) and SURMOUNT program (weight management). We do not restate efficacy percentages here as outcome promises — any figures you encounter should be framed as study findings from the FDA label or a published trial, not as a guarantee of personal results. Individual response varies, and only a licensed clinician can assess whether tirzepatide is appropriate for you.

Mounjaro — type 2 diabetes. The FDA label indicates Mounjaro as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults with type 2 diabetes. It is not indicated for type 1 diabetes. A provider prescribing Mounjaro is treating a diabetes diagnosis.

Zepbound — chronic weight management (and OSA). The FDA label indicates Zepbound, in combination with reduced-calorie diet and increased physical activity, for chronic weight management in adults who meet the weight criteria specified in the label (a body-mass-index threshold, with a lower threshold if at least one weight-related comorbidity is present). Per Lilly's 2024 announcement, Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Because the indications differ, the brand that is appropriate for you depends on your medical situation. A clinician determines eligibility during a consultation — reviewing your history, current medications, and labs as needed. Neither brand is available without a prescription, and no legitimate provider dispenses tirzepatide without a consultation.

Because the molecule is the same, the dosing schedule for Mounjaro and Zepbound is the same. Per Lilly's prescribing information, both are once-weekly subcutaneous injections that begin at a low starting dose and step up gradually:

• Starting dose: 2.5 mg once weekly (this is a starting/initiation dose, not a treatment dose).
• Titration: the dose is increased in increments over time — typically a step up roughly every four weeks as tolerated — through strengths of 5, 7.5, 10, 12.5 mg.
• Maximum dose: 15 mg once weekly per the prescribing information.

The slow titration is designed to reduce gastrointestinal side effects. A licensed provider sets and adjusts your specific dose and schedule; do not change a dose on your own. The injection is given once a week on the same day each week, and can be taken with or without food per the label.

This is the single biggest practical difference for most people. Insurance generally treats diabetes medication and weight-loss medication very differently. Many plans cover Mounjaro for a type 2 diabetes diagnosis (often with prior authorization), while excluding or heavily restricting coverage of weight-loss drugs like Zepbound — a longstanding gap in how many U.S. plans handle obesity treatment.

List prices. Eli Lilly lists Mounjaro at roughly $1,000 or more per month before insurance, and has offered cash-pay options for Zepbound through its LillyDirect Self Pay program, including single-dose vials priced below the pen list price. These figures change frequently and vary by dose and program eligibility — always verify the current price directly at lilly.com or with the dispensing pharmacy before relying on it.

Manufacturer access programs. Lilly operates LillyDirect, its direct channel that connects patients with telehealth and pharmacy fulfillment for Lilly medications including tirzepatide. (For context, NovoCare is the comparable program from Novo Nordisk, the maker of Ozempic and Wegovy — a different manufacturer.) Savings-card eligibility for the branded pens typically depends on having commercial insurance and is restricted for those on government plans like Medicare or Medicaid — check the specific terms on Lilly's site.

Because coverage is so plan-specific, the most reliable path is to have a licensed provider and pharmacy run your actual benefits. Telehealth platforms can help here, but the underlying price is set by the manufacturer and your insurer, not by the platform.

On reputable telehealth platforms, a licensed clinician — not an algorithm and not you — makes the prescribing decision after a consultation. The logic generally runs like this:

• If you have a type 2 diabetes diagnosis, branded tirzepatide for you would be Mounjaro, and the clinician treats it as diabetes care.
• If you are seeking treatment for weight and meet the label's criteria, the brand is Zepbound, prescribed for chronic weight management.
• If you have obstructive sleep apnea with obesity, Zepbound now carries an FDA indication for that as of Lilly's 2024 announcement.

Several telehealth providers in this space connect patients with licensed clinicians who can evaluate eligibility for GLP-1 / tirzepatide therapy. Examples of platforms that operate in the GLP-1 telehealth category include Henry Meds (henrymeds), Ivim Health (ivim), ShedRx (shedrx), Eden (eden), MEDVi (medvi), and Measured Health (measured), among others. For the branded products specifically, LillyDirect (lillydirect) is the manufacturer's own direct channel. Coverage, available medications, and whether a platform offers branded vs. compounded products vary — confirm current details with each provider before enrolling.

A clinician may decline to prescribe tirzepatide if it is not appropriate for your health profile. That is a feature of legitimate care, not a barrier to route around.

You will see 'compounded tirzepatide' marketed at lower prices. It is important to understand what that is and is not. Compounded tirzepatide is NOT FDA-approved. It is not Mounjaro and it is not Zepbound. Compounded drugs are prepared by compounding pharmacies and are not reviewed by the FDA for safety, effectiveness, or quality the way the branded products are.

During the official shortage of tirzepatide, compounding was more widely permitted under specific federal rules. The FDA has stated that tirzepatide is no longer in shortage, which changes what compounding is allowed — the regulatory situation has shifted, so verify the current status before assuming a compounded product is available or appropriate. Any tirzepatide — branded or compounded — still requires a valid prescription from a licensed provider after a consultation. Be skeptical of any source offering to ship tirzepatide without a prescription or consultation, or selling 'research chemical' tirzepatide; those are not legitimate medical channels.

If cost is the driver, discuss FDA-approved options and manufacturer cash-pay programs (such as LillyDirect Self Pay vials for Zepbound) with a licensed provider rather than assuming compounded is the only affordable route.

Per the FDA labeling, the most commonly reported side effects of tirzepatide are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal discomfort — which is part of why the dose is titrated slowly. Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies; the label states it should not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

This is not a complete list of risks, warnings, or interactions. Only a licensed clinician who reviews your full medical history can assess whether tirzepatide is appropriate for you and monitor you while on it. Report side effects to your provider, and seek emergency care for severe symptoms such as signs of a serious allergic reaction or pancreatitis as described in the label.

GLP-1 Samples is an independent editorial resource. We review and compare licensed telehealth providers and publicly available drug information. We do not sell, ship, prescribe, or dispense medication, and we do not provide medical advice. Editorial placement on this site is never for sale; we may earn a commission if you sign up with a provider through our links, but that does not influence which providers we cover or how we assess them.

This article is for adults 18 and older and is educational, not a substitute for professional medical advice, diagnosis, or treatment. Prescription medications including tirzepatide require a consultation with a licensed healthcare provider. Prices and coverage details are attributed to the manufacturer or provider as of writing and change frequently — verify current information at the source. Compounded medications are not FDA-approved.